Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JANUS Tacrolimus-eluting Carbostent
- Development stage
- Unknown
- Lead developer
- LivaNova
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Implant, Percutaneous
01
Overview
The JANUS Tacrolimus-eluting Carbostent is a polymer-free drug-eluting stent (DES) developed by Sorin Group (CID) for the treatment of coronary artery disease. It features a stainless steel platform coated with a thromboresistant pyrolytic carbon film (Carbofilm) and incorporates deep reservoirs on its abluminal surface. These reservoirs are loaded with tacrolimus, a small molecule immunosuppressant that acts as an antiproliferative agent to inhibit smooth muscle cell proliferation and prevent restenosis. The design allows for targeted drug delivery directly to the vessel wall without the need for a polymer carrier, potentially reducing long-term inflammatory responses associated with polymer-based stents. The device has been evaluated in clinical trials such as JUPITER I and JUPITER II.
- Brand names
- JANUS
- Other names
- JANUS stentTacrolimus-eluting Carbostent
02
Targets
FKBP1ACN (Calcineurin)
Beyond the preview
Go deeper on JANUS Tacrolimus-eluting Carbostent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JANUS Tacrolimus-eluting Carbostent.